Eagle Health Investments LP Purchases Shares of 27,100 Disc Medicine, Inc. $IRON
Eagle Health Investments LP has acquired 27,100 shares of Disc Medicine, Inc. (NASDAQ:IRON) worth $2.15 million, representing a new position for the firm. Despite recent insider selling and a slight earnings miss, institutional ownership remains high at 83.70%, and analysts maintain a "Moderate Buy" rating with an average price target of $105.30.
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are ...
Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the company's bitopertin program. The FDA's decision, citing uncertainties in the New Drug Application (NDA) requiring additional evidence, caused Disc Medicine's stock price to drop 22% on February 13, 2024. The firm encourages investors who suffered losses to contact them for information on joining a prospective class action.
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, causing a 22% stock drop. Investors who suffered losses are encouraged to contact the firm about joining a prospective class action to seek compensation. The firm highlights its track record in securities class actions.
IRON: APOLLO study enrollment exceeded targets, signaling high demand and unmet need for EPP therapies
Enrollment in Disc Medicine's APOLLO study for bitopertin surpassed expections, indicating a high demand and larger-than-expected patient population for EPP therapies. The company also reported promising efficacy for DISC-0974 in myelofibrosis and plans to expand into IBD and sickle cell disease. These updates are based on Disc Medicine, Inc.'s H.C. Wainwright 4th Annual BioConnect Investor Conference Audio Transcript from May 19, 2026.
DNB Asset Management AS Raises Stock Holdings in Disc Medicine, Inc. $IRON
DNB Asset Management AS significantly increased its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 1,425.8% in the fourth quarter, now owning 84,255 shares valued at $6.7 million. This substantial increase reflects strong institutional interest, with hedge funds and other institutions collectively holding 83.7% of the company's stock. Despite missing EPS estimates in its last earnings report, analysts maintain a "Moderate Buy" consensus rating with an average target price of $105.30.
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
The Rosen Law Firm is investigating potential securities class action claims against Disc Medicine, Inc. (NASDAQ: IRON) after the company's stock price fell 22% on February 13, 2026. This drop followed the FDA's issuance of a Complete Response Letter for Disc Medicine's bitopertin program, citing uncertainties requiring additional evidence for approval. Shareholders who purchased Disc Medicine securities are encouraged to contact the law firm to learn about joining the prospective class action.
Should Disc Medicine’s RALLY-MF Data and Wider Pipeline Reveal a Pivotal Inflection for IRON’s Narrative?
Disc Medicine (NASDAQ: IRON) reported a Q1 2026 net loss of US$63.5 million, emphasizing that its investment narrative increasingly hinges on clinical progress, particularly due to upcoming RALLY-MF phase 2 data presentations at the European Hematology Association Congress. While these presentations keep the pipeline in focus, rising losses and insider selling remain key risks for investors. The article suggests that despite recent share price weakness, the stock might still be overvalued and encourages investors to independently assess its fair value.
Disc Medicine, Inc. - Common Stock (NQ: IRON)
This page provides recent news headlines and financial information for Disc Medicine, Inc. (Nasdaq: IRON). The news covers a range of topics including investor alerts regarding legal investigations, FDA updates on drug reviews, insider stock sales, financial results, and presentations at investor conferences. The content highlights Disc Medicine's various activities and market performance between October 2025 and February 2026.
Cantor Fitzgerald Remains a Buy on Disc Medicine (IRON)
Cantor Fitzgerald analyst Kristen Kluska has reiterated a Buy rating on Disc Medicine (IRON) and set a price target of $125.00, following the company's shares closing at $68.53. The analyst has a strong track record, and the overall consensus for Disc Medicine is a Strong Buy. Despite a quarterly net loss of $63.5 million, insider sentiment is negative due to recent share sales.
Morgan Stanley Raises Price Target on Disc Medicine to $80 From $75, Keeps Overweight Rating
Morgan Stanley has increased its price target for Disc Medicine (NASDAQ:IRON) to $80 from $75, while maintaining an Overweight rating on the stock. This adjustment follows several recent updates from Disc Medicine, including its Q1 2026 earnings report and the completion of enrollment for its Phase 3 APOLLO trial of bitopertin. The company specializes in treatments for serious hematologic diseases and has multiple pipeline candidates.
Disc Medicine, Inc. Announces Oral Presentation of Phase 2 RALLY-MF Trial Data for DISC-0974 at EHA 2026 Congress and Corporate Update Call
Disc Medicine, Inc. will present Phase 2 RALLY-MF trial data for DISC-0974 in anemia of myelofibrosis at the European Hematology Association (EHA) 2026 Congress. The presentation will highlight strong response rates across various patient cohorts, and the company will also provide updates on its bitopertin and DISC-3405 programs. Following the EHA Congress, Disc Medicine will host a conference call on June 15 to discuss the presented data and future directions.
Experimental anemia treatment shows 70% response in myelofibrosis trial
Disc Medicine announced that it will present data from its hematology pipeline, including promising Phase 2 RALLY-MF trial results for DISC-0974 in myelofibrosis anemia, at the European Hematology Association (EHA) 2026 Congress. The RALLY-MF trial showed an overall response rate of 70% in evaluable myelofibrosis patients with anemia, with significant major response rates across different transfusion-dependent cohorts. The company will also provide updates on its erythropoietic protoporphyria (EPP) program and its DISC-3405 trial for polycythemia vera.
Vanguard Group Inc. Acquires 319,621 Shares of Disc Medicine, Inc. $IRON
Vanguard Group Inc. increased its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 22.1% in the fourth quarter, acquiring an additional 319,621 shares, bringing its total holdings to 1,767,680 shares valued at $140.4 million. Despite institutional interest, the company faces mixed sentiment with recent insider selling of 59,410 shares and a reported quarterly EPS of -$1.65, missing analyst expectations. Wall Street analysts currently rate Disc Medicine as a "Moderate Buy" with an average price target of $104.80.
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, causing a 22% stock drop. The firm encourages investors who purchased Disc Medicine securities to inquire about a prospective class action to recover losses. They highlight their track record in investor rights law and class action settlements.
Stifel Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $111
Stifel has reiterated its Buy rating on Disc Medicine (IRON.US), maintaining a target price of $111. This indicates continued confidence from Stifel in the company's prospects.
Hear Disc Medicine leaders in two live investor conference webcasts
Disc Medicine (NASDAQ: IRON) announced its participation in two upcoming investor conferences: the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 19th and the Jefferies Global Healthcare Conference on June 3rd. Management will host fireside chats at both events. Live webcasts and archived replays will be accessible via the company's investor relations website for those interested in attending or revisiting the presentations.
Disc Medicine to Participate in Upcoming Investor Conferences
Disc Medicine, Inc. announced its management will participate in two upcoming investor conferences: the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 19th and the Jefferies Global Healthcare Conference on June 3rd. Live webcasts and archived replays of these fireside chats will be available on the company's investor relations website. The clinical-stage biopharmaceutical company focuses on developing treatments for serious hematologic diseases.
Number of shareholders of Disc Medicine, Inc. – NASDAQ:IRON
The article focuses on the number of shareholders for Disc Medicine, Inc. (NASDAQ:IRON). It provides a snapshot of the company's financial data on TradingView, indicating that the market is currently closed. The page also mentions the data sources and copyright information for the financial and reference data displayed.
Disc Medicine to Participate in Upcoming Investor Conferences
Disc Medicine, a clinical-stage biopharmaceutical company, announced its participation in two upcoming investor conferences: the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 19th and the Jefferies Global Healthcare Conference on June 3rd. Live webcasts of these fireside chats will be available on the company's investor relations website, with archived replays provided afterward. The company focuses on developing novel treatments for serious hematologic diseases.
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are ...
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter regarding the company's new drug application in February 2026, causing a 22% stock drop. Shareholders who have incurred losses are encouraged to contact the law firm to learn about joining a prospective class action lawsuit for compensation without out-of-pocket fees.
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following a 22% stock price drop on February 13, 2026. This decline occurred after the FDA issued a Complete Response Letter for Disc Medicine's bitopertin program, citing uncertainties that require additional evidence for approval. The firm encourages investors who suffered losses to contact them regarding a class action lawsuit.
A Look At Disc Medicine (IRON) Valuation As Key APOLLO Phase 3 And Pipeline Milestones Progress
Disc Medicine (IRON) has advanced its clinical pipeline, notably by completing enrollment for the APOLLO Phase 3 trial. While recent market performance has been mixed, the company shows strong long-term momentum. The article delves into Disc Medicine's valuation, examining its price-to-book ratio and discounted cash flow analysis, and offers a cautiously optimistic outlook for investors.
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, causing a 22% stock drop. Investors who purchased Disc Medicine securities and suffered losses are encouraged to contact the firm to discuss joining a prospective class action for compensation. The firm highlights its track record in securities class actions and derivative litigation.
HC Wainwright Cuts Earnings Estimates for Disc Medicine
HC Wainwright has revised its earnings estimates for Disc Medicine (NASDAQ:IRON), lowering its Q3 2026 and FY2026 EPS forecasts. Despite these near-term cuts, the firm raised its long-term profitability forecasts for FY2029 and FY2030, indicating a mixed outlook with improved longer-term model assumptions. The article also details recent analyst ratings, insider transactions, institutional holdings, and key news influencing the company's stock.
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
The Rosen Law Firm is investigating potential securities class action claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program on February 13, 2026, causing a 22% stock drop. The firm alleges Disc Medicine may have provided misleading business information. Investors who purchased Disc Medicine securities are encouraged to contact the Rosen Law Firm to learn about joining the prospective class action.
H.C. Wainwright Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $118
H.C. Wainwright has reiterated its Buy rating for Disc Medicine (IRON.US) and maintained its target price at $118. This indicates continued confidence from the analyst firm in the company's prospects.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON
Pomerantz LLP is investigating potential securities fraud by Disc Medicine, Inc. (NASDAQ: IRON) after its stock price dropped following two negative announcements. Reuters reported a delay in drug review due to FDA concerns, causing a 7.84% stock decline on January 15, 2026. Subsequently, the FDA issued a Complete Response Letter for bitopertin's New Drug Application on February 13, 2026, leading to a further 21.91% fall in Disc's stock.
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, causing a 22% stock drop. Investors who purchased Disc Medicine securities are encouraged to contact the law firm to inquire about joining a prospective class action seeking to recover investor losses. The firm emphasizes its experience in securities class actions and shareholder derivative litigation.
Disc Medicine Q1 Net Loss Widens
Disc Medicine's net loss widened in the first quarter. Unity Software also reported its fourth-quarter financial results, with revenue increasing 35% year-over-year to $609 million, exceeding estimates, but reported a quarterly loss of 66 cents per share. The full details of Disc Medicine's Q1 results are not included without logging in.
Disc Medicine (NASDAQ:IRON) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS
Disc Medicine (NASDAQ:IRON) reported quarterly earnings of ($1.65) per share, missing the consensus estimate by $0.03. Following the announcement, IRON shares traded down, and internal sales included the CEO and COO selling shares. Despite the earnings miss and insider sales, analysts maintain a "Moderate Buy" consensus rating with a target price of $104.80.
How Investors Are Reacting To Disc Medicine (IRON) After FDA Letter Triggers Shareholder Investigation
Rosen Law Firm has launched a shareholder investigation into Disc Medicine, Inc. (IRON) following an FDA Complete Response Letter regarding its bitopertin program. This regulatory setback and legal scrutiny are raising questions about the company's prior disclosures and communication practices with investors. The investigation adds uncertainty to Disc Medicine's investment narrative, particularly regarding regulatory timing and potential delays, despite its prior focus on accelerated approval paths and a strong cash runway.
Earnings Flash (IRON) Disc Medicine Posts Q1 Net Loss $1.65 a Share, vs. FactSet Est of $1.65 Loss
Disc Medicine (IRON) reported a net loss of $1.65 per share for the first quarter, which aligns with the consensus estimate from FactSet. The company's Q1 results indicate its financial performance matched analyst expectations for the period.
Disc Medicine 1Q 2026: Net income $(63.5M), EPS $(1.65) — 10-Q Summary
Disc Medicine, Inc. reported a widened net loss of $63.5 million, or $(1.65) per diluted share, for the first quarter of 2026, compared to a net loss of $34.1 million, or $(1.02) per diluted share, in Q1 2025. The company continues to advance its clinical pipeline, with key milestones including completing enrollment for the Phase 3 APOLLO trial of bitopertin and progressing other drug candidates. Disc Medicine maintains a strong cash position of $730.2 million, expected to fund operations into 2029.
Disc Medicine finishes Phase 3 rare-disease trial, eyes Q4 data
Disc Medicine announced the completion of enrollment for its Phase 3 APOLLO trial of bitopertin for erythropoietic protoporphyria (EPP), with topline data expected in Q4 2026. The company also reported a widening net loss in Q1 2026 to $63.5 million, driven by increased R&D and SG&A expenses, but bolstered its cash reserves to $730.2 million, providing a runway into 2029. Additionally, updated Phase 2 data for DISC-0974 in myelofibrosis anemia will be presented at ASCO, and initial data for DISC-3405 in polycythemia vera and sickle cell disease are also anticipated in Q4 2026.
Disc Medicine (NASDAQ: IRON) posts Q1 2026 loss and advances late-stage trials
Disc Medicine reported a widened net loss of $63.5 million ($1.65 per share) for Q1 2026, primarily due to increased investment in its clinical pipeline, with R&D expenses rising to $45.9 million and SG&A to $23.6 million. Despite the loss, the company ended the quarter with a strong cash position of $730.2 million, projected to fund operations into 2029. Disc Medicine also highlighted significant progress in its late-stage trials, including the completion of enrollment for the Phase 3 APOLLO bitopertin study and anticipated data readouts for multiple programs in Q4 2026.
How Investors Are Reacting To Disc Medicine (IRON) After FDA Letter Triggers Shareholder Investigation
Disc Medicine (IRON) is facing a shareholder investigation following an FDA Complete Response Letter on its bitopertin program. This regulatory setback and legal scrutiny raise concerns about the company's disclosure practices and its communication of clinical and regulatory developments. Investors are now evaluating the impact of these events on Disc Medicine's investment narrative, especially given that the company's shares might be trading above fair value.
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following a 22% stock price drop on February 13, 2026. This decline occurred after the FDA issued a Complete Response Letter for Disc Medicine's bitopertin program, citing uncertainties that require additional evidence for approval. The firm encourages investors who suffered losses to contact them for potential class action participation.
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine, Inc. (NASDAQ: IRON) shareholders. This follows allegations that Disc Medicine may have issued materially misleading business information, leading to a 22% stock price drop on February 13, 2026, after the FDA issued a Complete Response Letter regarding its bitopertin program. Investors are encouraged to contact the firm to join a prospective class action to recover losses.
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, leading to a 22% stock price drop. The firm encourages investors who purchased Disc Medicine securities to inquire about joining a prospective class action to recover investor losses. The investigation aims to determine if Disc Medicine issued materially misleading business information.
Disc Medicine, Inc. $IRON Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH
Universal Beteiligungs und Servicegesellschaft mbH has significantly increased its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 138.7%, now holding 27,301 shares valued at $2.17 million. Despite institutional investors owning 83.7% of the company, several analysts have recently cut price targets, though the consensus remains a "Moderate Buy." Insiders, however, have been net sellers, with over $3.84 million in shares sold in the last 90 days.
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, leading to a 22% stock price drop on February 13, 2026. The firm is preparing a class action lawsuit to recover investor losses, citing allegations of materially misleading business information. Investors who purchased Disc Medicine securities are encouraged to contact the firm to join the prospective class action.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON
Pomerantz LLP is investigating potential securities fraud claims against Disc Medicine, Inc. (NASDAQ: IRON) after the company's stock price dropped significantly following two announcements. The first drop occurred after Reuters reported that a Disc drug faced FDA review delays due to safety and efficacy concerns. The second, larger drop, followed the FDA's issuance of a Complete Response Letter for bitopertin, citing a lack of evidence linking the drug's effect to sunlight exposure endpoints in trials.
Pictet Asset Management Holding SA Grows Stock Holdings in Disc Medicine, Inc. $IRON
Pictet Asset Management Holding SA significantly increased its stake in Disc Medicine, Inc. ($IRON) by 10,968.6% in Q4, now owning 394,374 shares valued at $31.3 million. Other hedge funds also adjusted their positions, with institutional investors and hedge funds owning 83.70% of the stock. Insider trading activity included sales by CFO Jean M. Franchi and William Jacob Savage, while analysts have a "Moderate Buy" consensus rating with a target price of $104.80.
Disc Medicine (IRON) Projected to Post Earnings on Thursday
Disc Medicine (NASDAQ:IRON) is forecasted to report its Q1 2026 earnings before market open on Thursday, May 7th, with analysts expecting an EPS of -$1.645 and revenue of $0.438 million. Despite recent price target cuts, analysts broadly assign a "Moderate Buy" rating with an average target of $104.80. Recent insider selling by the CEO and CFO has also been noted, though institutional investors have increased their positions in the company.
[ARS] Disc Medicine, Inc. SEC Filing
This article announces an ARS SEC filing by Disc Medicine, Inc. (NASDAQ: IRON) dated April 28, 2026. The filing has a low impact and neutral sentiment. It provides links to view the full PDF document on SEC EDGAR and an overview of Disc Medicine, Inc.'s stock information and recent news.
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, causing Disc Medicine's stock to fall 22%. The firm encourages investors who suffered losses to contact them for a prospective class action.
Disc Medicine prices upsized securities offering to raise total $250M
Disc Medicine has priced an upsized underwritten public offering of 11,029,412 shares of its common stock at $17.00 per share, aiming to raise approximately $187.5 million. Concurrently, the company will conduct a concurrent private placement of pre-funded warrants to purchase 3,676,470 shares at $16.999 per pre-funded warrant, with an additional option for underwriters to purchase up to 2,205,882 shares. The total expected gross proceeds from both offerings are about $250.0 million before deductions.
Will Insider 10b5-1 Sales and New ASCO Data Shift Disc Medicine's (IRON) Narrative?
Disc Medicine (IRON) recently saw its Chief Medical Officer sell shares under a pre-arranged plan, coinciding with continued progress on its lead program, APOLLO, and upcoming data presentation for DISC-0974 at ASCO. The article examines how these events impact the company's investment profile, suggesting that the ASCO presentation could elevate DISC-0974 as a secondary catalyst beyond its primary drug. Despite potential upsides, the company faces ongoing financial and regulatory risks, with its stock possibly trading above fair value.
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine, Inc. (NASDAQ: IRON) shareholders. This follows a 22% stock drop on February 13, 2026, after the U.S. FDA issued a Complete Response Letter for Disc Medicine's bitopertin new drug application due to efficacy uncertainties. The firm encourages investors who purchased Disc Medicine securities to inquire about a class action for compensation.
Disc Medicine plunges on FDA complete response letter for bitopertin
Disc Medicine's stock significantly dropped following the FDA's complete response letter for bitopertin, indicating that the drug will not be approved in its current form. While the specific reasons for the rejection are not detailed in this snippet, such letters typically highlight issues related to efficacy, safety, or manufacturing. This news is a major setback for Disc Medicine and its investors, impacting the company's immediate valuation and future development plans for bitopertin.
